SoftBank Group Q1 Income Before Tax Rises; Net Sales Up 15.6%

SoftBank Group Corp. (SFTBY.PK,SFTBF.PK) reported first quarter income before income tax of 1.29 trillion yen, an increase of 55.0% year on year. The Group recorded a gain on investments of 1.26 trillion yen, up 28.5% from prior year.

Net income from continuing operations attributable to owners of the parent increased to 761.51 billion yen from 521.14 billion yen, previous year. Earnings per share from continuing operations was 368.10 yen compared to 227.93 yen. Net income attributable to owners of the parent was 761.5 billion yen, down 39.4% from prior year as net income from discontinued operations of 734.5 billion yen was recorded in the same period of the previous fiscal year, primarily reflecting gain relating to loss of control of Sprint.

First-quarter net sales improved to 1.48 trillion yen from 1.28 trillion yen, previous year.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The U.S. Food and Drug Administration (FDA) approved Boehringer Ingelheim's Cyltezo as the first interchangeable biosimilar to AbbVie's top-selling drug Humira or adalimumab. Cyltezo, originally approved in August 2017, is both biosimilar to, and interchangeable with Humira for Cyltezo's approved uses. The Food and Drug Administration may be planning to allow people to receive Covid-19 vaccine booster shot that is different from the initial dose, reports indicate. The agency is likely to make the announcement on mix and match approach on coronavirus booster vaccines on Wednesday. The move will be part of FDA's expected authorization of boosters for the Moderna and Johnson & Johnson vaccines. Drug major Johnson & Johnson on Tuesday raised again its forecast for fiscal 2021 earnings and sales, which are above market view, after reporting higher results in the third quarter. The company's quarterly adjusted earnings also beat market estimates. In pre-market activity on the NYSE, JNJ shares were gaining around 1.24 percent to trade at $162.10.
Follow RTT